Current Edition

acute myeloid leukemia

ASH: Astellas looks for silver linings in failed Xospata combo trial

Eying growth in oncology, Astellas has suffered an R&D setback for acute myeloid leukemia drug Xospata (gilteritinib). The med flunked a combo trial with Bristol …

Continue Reading →
acute myeloid leukemia

Bayer targets 100% green packaging for consumer health brands by 2030 as part of €100 million sustainability plan

Eying growth in oncology, Astellas has suffered an R&D setback for acute myeloid leukemia drug Xospata (gilteritinib). The med flunked a combo trial with Bristol …

Continue Reading →
Amgen

For pharmas dealing with HCPs, the future is digital first—and sales reps 2nd

While many people are suffering from Zoom fatigue and looking forward to in-person meetups, that isn’t really the case when it comes to HCPs and …

Continue Reading →
Autoimmune Diseases

Bristol Myers Squibb’s next-gen autoimmune med starts high-stakes FDA review amid classwide JAK scrutiny

After the FDA slapped an updated safety warning on marketed oral JAK inhibitors for inflammatory diseases, market watchers have started worrying about other candidates in …

Continue Reading →
Aimovig

Amgen’s Otezla, Repatha and biosimilars put on notice, with challenging years ahead

Some of Amgen’s key businesses are drawing concerns as competition looms. Amgen’s 2022 sales could be about $26.3 billion, or $700 million lower than industry …

Continue Reading →
BMS

Bristol Myers Squibb’s Opdivo posts another win in early lung cancer, but debate over treatment approach likely remains

Bristol Myers Squibb has expanded Opdivo’s first-in-class win in pre-surgery non-small cell lung cancer, teeing up a potential FDA filing. Opdivo added to chemotherapy before …

Continue Reading →
Acceleron

Bristol Myers Squibb, after passing on Acceleron, now eyes Aurinia takeout: Bloomberg

It wasn’t long ago that Bristol Myers Squibb ran the numbers on potentially buying Acceleron Pharma, but that deal didn’t come together, and the biotech …

Continue Reading →
Bristol Myers Squibb

Bristol Myers Squibb previews new ‘transformation’ corporate brand campaign at annual global patients’ event

Bristol Myers Squibb’s new corporate campaign celebrates transformation—of science, the pharma industry and patients’ lives. It’s the pharma’s first corporate campaign since BMS’ own transformation …

Continue Reading →
Bristol Myers Squibb

In newly diagnosed stomach cancer, 2 Opdivo-Yervoy flops show immunotherapy alone might not be the answer

Bristol Myers Squibb boasts a historic go-ahead for Opdivo plus chemotherapy as the first immunotherapy regimen for previously untreated stomach cancer. But the PD-1 inhibitor …

Continue Reading →
AbbVie

CEOs of AbbVie, BMS, Lilly, GSK and more raise concerns about Washington’s intensifying drug-pricing push

As officials in Washington weigh contentious drug-pricing measures, there’s even more evidence that pharma companies are worried about potential reform. In an open letter to …

Continue Reading →